On November 18, 2021, Generate Biomedicines, Inc. closed the transaction. The company has issued 31,223,629 series B preferred stock for gross proceeds of $370,000,003.65 in the transaction. The transaction included participation from several institutional co-investors including new investors, a wholly-owned subsidiary of Abu Dhabi Investment Authority, Alaska Permanent Fund, Altitude Life Science Ventures, Arch Venture Partners, L.P., Fidelity Management & Research Company LLC, Morningside Ventures Limited, funds and accounts advised by T. Rowe Price Group, Inc., and returning investor, Flagship Pioneering.